Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Operating Expenses (2016 - 2025)

Lipocine (LPCN) has disclosed Operating Expenses for 13 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 32.13% year-over-year to $3.5 million, compared with a TTM value of $10.6 million through Sep 2025, down 19.55%, and an annual FY2024 reading of $12.4 million, down 18.08% over the prior year.
  • Operating Expenses was $3.5 million for Q3 2025 at Lipocine, up from $3.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $4.4 million in Q1 2024 and bottomed at $1.9 million in Q4 2024.
  • Average Operating Expenses over 5 years is $3.2 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 40.3% in 2023, then plummeted 50.3% in 2025.
  • Year by year, Operating Expenses stood at $3.3 million in 2021, then dropped by 22.44% to $2.6 million in 2022, then grew by 9.71% to $2.8 million in 2023, then plummeted by 30.74% to $1.9 million in 2024, then skyrocketed by 78.61% to $3.5 million in 2025.
  • Business Quant data shows Operating Expenses for LPCN at $3.5 million in Q3 2025, $3.0 million in Q2 2025, and $2.2 million in Q1 2025.